BioBlast Pharma Announces Pricing of $6.7 Million Registered Direct Offering
Mar 17, 2016 11:00 am UTC| Business
NEW HAVEN, Conn., March 17, 2016 -- BioBlast Pharma Ltd. (Nasdaq:ORPN) (the "Company" or "ORPN") announced that it has entered into definitive securities purchase agreements with two healthcare focused institutional...
Mar 17, 2016 11:00 am UTC| Business
MORRIS PLAINS, N.J., March 17, 2016 -- Immunomedics, Inc., (Nasdaq:IMMU) today announced that two abstracts have been accepted for oral presentation in a Clinical Trials Minisymposium session at the 2016 American...
Mar 17, 2016 11:00 am UTC| Business
NEW YORK, March 17, 2016 -- Taboola®, the leading global discovery platform, today unveiled its latest innovation for the native advertising market. “Taboola Native,” a free and white-labelled version of the company’s...
The Michaels Companies Announces Record Fourth Quarter and Fiscal 2015 Financial Results
Mar 17, 2016 11:00 am UTC| Business
Fourth quarter comparable store sales increased 3.1%, or 4.7% on a constant currency basisFourth quarter total net sales increased 4.6% to $1.7 billion, or 6.4% on a constant currency basis Fourth quarter operating income...
Elite Announces U.S. FDA Priority Review Designation for SequestOx™ NDA
Mar 17, 2016 11:00 am UTC| Business
NORTHVALE, N.J., March 17, 2016 -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today announced that the New Drug Application (NDA) for SequestOXTM (ELI-200), Elite’s lead opioid abuse-deterrent...
Neos Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results
Mar 17, 2016 11:00 am UTC| Business
Launch of Adzenys XR-ODT in Second Quarter of 2016 Company to Host Conference Call at 8:30am ET Today DALLAS/FORT WORTH, Texas, March 17, 2016 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company...
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2015 Financial Results
Mar 17, 2016 11:00 am UTC| Business
BERKELEY HEIGHTS, N.J., March 17, 2016 -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target the various phases...